<?xml version='1.0' encoding='utf-8'?>
<document id="22864874"><sentence text="A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer."><entity charOffset="19-29" id="DDI-PubMed.22864874.s1.e0" text="vinflunine" /></sentence><sentence text="To determine the recommended dose (RD) of vinflunine in combination with trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and to investigate potential pharmacokinetic (PK) interactions"><entity charOffset="42-52" id="DDI-PubMed.22864874.s2.e0" text="vinflunine" /></sentence><sentence text="" /><sentence text="In the first part of the study, two dose levels of vinflunine given every 3 weeks were explored (280 and 320 mg/m(2)) combined with trastuzumab (4 mg/kg loading dose and 2 mg/kg weekly)"><entity charOffset="51-61" id="DDI-PubMed.22864874.s4.e0" text="vinflunine" /></sentence><sentence text=" For each level of dose, six patients were enrolled to determine the RD for phase 2 studies (RP2S)" /><sentence text=" In the second part of the study, 18 additional patients at RP2S have been evaluated to confirm safety and investigate preliminary antitumor activity" /><sentence text="" /><sentence text="The RD was 320 mg/m(2) according to the dose escalation plan" /><sentence text=" Eleven of 15 additional patients who received this dose experienced dose-limiting toxicities, leading to a reduction in the RD to 280 mg/m(2)" /><sentence text=" When compared to prior trials when vinflunine was used as a single agent, neither vinflunine total blood clearance nor trastuzumab serum concentrations were modified when the drugs were combined"><entity charOffset="36-46" id="DDI-PubMed.22864874.s10.e0" text="vinflunine" /><entity charOffset="83-93" id="DDI-PubMed.22864874.s10.e1" text="vinflunine" /><pair ddi="false" e1="DDI-PubMed.22864874.s10.e0" e2="DDI-PubMed.22864874.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22864874.s10.e0" e2="DDI-PubMed.22864874.s10.e1" /></sentence><sentence text=" All patients were evaluable, and the overall response rate was 73" /><sentence text="3 % (95 % CI 54" /><sentence text="1-87" /><sentence text="7)" /><sentence text=" The median progression-free survival was 11" /><sentence text="3 months (95 % CI 9" /><sentence text="4-21" /><sentence text="0)" /><sentence text=" At the dose of 280 mg/m(2), grade 3-4 neutropenia were seen in 4 patients (44" /><sentence text="4 %) without febrile neutropenia" /><sentence text=" Non-hematologic grade 4 toxicities were not reported while grade 3 peripheral sensory neuropathy concerned 2 patients (22" /><sentence text="2 %)" /><sentence text="" /><sentence text="The RD of vinflunine in combination with the standard regimen of trastuzumab is 280 mg/m(2) every 3 weeks"><entity charOffset="10-20" id="DDI-PubMed.22864874.s24.e0" text="vinflunine" /></sentence><sentence text=" No mutual PK drug-drug interaction was seen" /><sentence text=" This regimen appears to be active with a favorable safety profile" /><sentence text=" Its role in HER2-positive MBC treatment needs to be defined in prospective comparative clinical trials" /><sentence text="" /></document>